Large addressable market Pattern hair loss affects tens of millions in the US for both men and women, with no new approved prescriptions in ~30 years, signaling strong demand and a large, underserved market for a non-hormonal oral therapy.

First-mover potential Lead candidate VDPHL01 is positioned as the first non-hormonal oral treatment for hair regrowth, offering a differentiated clinical profile and a potential single-source solution for patients seeking alternatives to hormonal therapies.

Clinical momentum Positive topline results in both male and female arms of Phase 2/3 studies, with ongoing data presentations and upcoming pivotal readouts, creating opportunities to engage KOLs, payers, and patient advocacy groups ahead of potential FDA submission.

Financial runway Company demonstrates substantial funding and significant revenue potential, supported by a strong investor sentiment and a recent stock upgrade, enabling more expansive clinical development, BD partnerships, and market access activities.

Strategic partnerships Dermatologist-founded brand with direct clinical experience in pattern hair loss positions Veradermics well for collaborations with dermatology clinics, specialty pharmacies, and cosmetics/dermatology retailers seeking evidence-based, prescription-grade solutions.